No Data
No Data
China Resources Double-Crane Pharmaceutical H1 Profit Up 6%, Operating Income Rises 1.5%
China Resources Double-Crane Pharmaceutical 2024 Semi-Annual Report
china resources double-crane pharmaceutical 2024 interim report summary
Express News | China Resources Double-Crane Pharma H1 Net Profit up 6.3% Y/Y
China Resources Double-Crane PharmaceuticalLtd's (SHSE:600062) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns
China Resources Double-Crane Pharmaceutical (600062.SH): Subsidiary passes GMP compliance inspection.
China Resources Double-Crane Pharmaceutical (600062.SH) announced that its subsidiary, Zhejiang Xinsaike Pharmaceutical Co., Ltd., obtained the announcement of the GMP compliance inspection results from the Zhejiang Provincial Drug Administration. In this drug GMP compliance inspection, the API of moxidectin hydrochloride was the first drug GMP compliance inspection before listing. It is a new product added to the original production line, and the newly added investment in production equipment and facilities in the above workshop is 1.163 million yuan (unaudited). The API of tramadol hydrochloride was the first time to pass the GMP compliance inspection after the new production line was put into operation. The production equipment and facilities in the above workshop are
No Data